Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Pfizer
(NY:
PFE
)
28.71
-0.17 (-0.59%)
Official Closing Price
Updated: 7:00 PM EDT, Aug 15, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Pfizer
< Previous
1
2
...
13
14
15
16
17
18
19
20
21
...
33
34
Next >
MarketBeat: Week in Review 12/05 – 12/09
December 10, 2022
The markets continue to have a lot to digest before there can be a Santa Claus raly. Here are some of the top stories our analysts were covering this week.
Via
MarketBeat
Topics
Economy
Electric Vehicles
Supply Chain
Exposures
Electric Vehicles
Interest Rates
Supply Chain
Pfizer Declares First-Quarter 2023 Dividend
December 09, 2022
From
Pfizer Inc.
Via
Business Wire
Can Pfizer, Johnson & Johnson Continue Outperforming the Index?
December 09, 2022
Large-cap pharmaceuticals Pfizer and Johnson & Johnson are outperforming the broader market in the past year, particularly in the past three months.
Via
MarketBeat
Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine in Children Under 5 Years
December 08, 2022
From
Pfizer Inc.
Via
Business Wire
AAPS Executive Director in Journal of American Physicians and Surgeons Discusses Whether Blood Clots After COVID Vaccines Are an Ignored Crisis
December 07, 2022
Despite official reassurances that adverse effects of COVID vaccines are rare or mild, some patients still have concerns, and social media is filled with reports. In the winter issue of the Journal of...
Via
Newswire.com
Exposures
COVID-19
U.S. FDA Accepts for Priority Review the Biologics License Application for Pfizer’s Respiratory Syncytial Virus Vaccine Candidate for the Prevention of RSV Disease in Older Adults
December 07, 2022
From
Pfizer Inc.
Via
Business Wire
Nanomedicine Market Size & Share Report 2022 : Reach at US$ 238.4 Bn and Grow at Healthy CAGR 10.1% During Forecast Period 2022-2028
December 06, 2022
"Emerging innovative technologies for drug delivery, the benefits of nanomedicine in various healthcare applications, and the increase in the demand for safe and inexpensive treatments drive the growth...
Via
SBWire
Pfizer and Clear Creek Bio to Collaborate on a Research Program Targeting SARS-CoV-2 Papain-Like Protease
December 06, 2022
From
Pfizer Inc.
Via
Business Wire
Pfizer Invites Public to Register for Webcast of Pfizer Near-Term Launches + High-Value Pipeline Day
December 01, 2022
From
Pfizer Inc.
Via
Business Wire
Roivant and Pfizer Form New Vant Company Focused on Developing TL1A Drug Candidate for Inflammatory and Fibrotic Diseases
December 01, 2022
From
Roivant Sciences
Via
GlobeNewswire
Cosmos Holdings May be a Long-Term Buy with Short-Term Risk
November 30, 2022
Cosmos Holdings stock is up 618% in November likely due to a short squeeze. This article explains why Cosmos Holdings may still be a good long-term investment
Via
MarketBeat
Topics
Intellectual Property
Exposures
Intellectual Property
Longwood Healthcare Leaders to Bring Together Several Hundred Top Biotech and Pharmaceutical Leaders on Jan. 5-6, 2023
November 30, 2022
Longwood Fund, an early-stage life science venture firm, will convene several hundred top biotech and pharmaceutical leaders at its Pre-JPM Longwood Healthcare Leaders meeting, hosted virtually via...
Via
Newswire.com
Exposures
Product Safety
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
November 28, 2022
From
Pfizer Inc.
Via
Business Wire
Nutraceutical Supplements Market to Witness Huge Growth : Glanbia, Pfizer, Bayer, DowDuPont
November 25, 2022
Understand focused approach and business strategies that competitors are keeping to reach target audience, Get one step closer to leaders and high growth emerging players of Nutraceutical Supplements...
Via
SBWire
Graphic design as a service Company Doozoo secures strategic investment partner, launches fresh branding and expands resource within USA to meet growing global demand.
November 22, 2022
Via
Get News
Arvinas Announces ARV-471 Achieves a Clinical Benefit Rate of 38% in Evaluable Patients and Continues to Show a Favorable Tolerability Profile in its Phase 2 Expansion Trial (VERITAC)
November 22, 2022
From
Arvinas Inc.
Via
GlobeNewswire
What the Latest Science Says About COVID-19 Testing and Treatment
November 17, 2022
Via
StatePoint Media
Topics
Death
Exposures
COVID-19
Death
While COVID-19 Drags On, Biotechs Introduce New Treatments & Vaccines to Combat Subvariants
November 16, 2022
EQNX::TICKER_START (OTCQB:BIXT),(NASDAQ:NVAX),(NYSE:PFE),(NASDAQ:MRNA),(NASDAQ:INO),(NASDAQ:BNTX) EQNX::TICKER_END
Via
FinancialNewsMedia
Exposures
COVID-19
Four Healthcare Stocks To Watch This Week
November 16, 2022
Healthcare has long been a wise investment, as the industry consistently grows yearly. Some analysts believe that trend will continue.
Via
MarketBeat
Can AbbVie Grow Revenue When Humira Biosimilars Hit The Market?
November 16, 2022
Shares of AbbVie have been in rally mode since late October. The company has newer drugs whose revenue could make up for declines due to Humira's patent expiry.
Via
MarketBeat
Topics
Intellectual Property
Exposures
Intellectual Property
Glisser Agrees Strategic Partnership with American Express Global Business Travel
November 14, 2022
Via
Get News
Physicians for Informed Consent Challenges the Basis for COVID-19 Vaccine Mandates
November 11, 2022
According to Physicians for Informed Consent, new data raise serious concerns over the risks of hospitalization in people vaccinated with the COVID-19 vaccine.
Via
Newswire.com
Topics
Death
Exposures
COVID-19
Death
The Dr. Erik Goluboff Scholarship for Future Medical Doctors Available in the United States
November 11, 2022
Via
Get News
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
November 11, 2022
From
Pfizer Inc.
Via
Business Wire
Is It Time To Pay Attention To This Acellular Biologic Pioneer That Says Its Clinical Trials Are Cheaper And Easier?
November 10, 2022
Learn more about Organicell Regenerative Medicine, Inc.from this latest report.
Via
TheNewswire.com
Exposures
COVID-19
Product Safety
NYSE:PFE Investor Alert: Investigation over Possible Securities Laws Violations by Pfizer Inc.
November 10, 2022
San Diego, CA -- (SBWIRE) -- 11/10/2022 -- Pfizer Inc. is under investigation over potential securities laws violations in connection with certain financial statements.
Via
SBWire
Drug Repurposing Market to Eyewitness Huge Growth by 2027 : Allergan, Astellas Pharma, Biovista, NuMedii
November 07, 2022
Stay up-to-date with Drug Repurposing Market research offered by AMA. Check how key trends and emerging drivers are shaping this industry growth.
Via
SBWire
Exposures
Product Safety
Pfizer’s Elranatamab Granted FDA Breakthrough Therapy Designation for Relapsed or Refractory Multiple Myeloma
November 03, 2022
From
Pfizer Inc.
Via
Business Wire
Pfizer and BioNTech Announce Updated Clinical Data for Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Substantially Higher Immune Response in Adults Compared to the Original COVID-19 Vaccine
November 04, 2022
From
Pfizer Inc.
Via
Business Wire
PFIZER REPORTS STRONG THIRD-QUARTER 2022 RESULTS AND RAISES 2022 OUTLOOK
November 01, 2022
From
Pfizer Inc.
Via
Business Wire
< Previous
1
2
...
13
14
15
16
17
18
19
20
21
...
33
34
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.